Bipolar Disorder News and Research RSS Feed - Bipolar Disorder News and Research

Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Symptoms of bipolar disorder are severe. They are different from the normal ups and downs that everyone goes through from time to time. Bipolar disorder symptoms can result in damaged relationships, poor job or school performance, and even suicide. But bipolar disorder can be treated, and people with this illness can lead full and productive lives.
Brain scans may help predict patients' response to antipsychotic drug treatment

Brain scans may help predict patients' response to antipsychotic drug treatment

Investigators at The Feinstein Institute for Medical Research have discovered that brain scans can be used to predict patients' response to antipsychotic drug treatment. The findings are published online in the latest issue of The American Journal of Psychiatry. [More]
UiO researchers test new nasal spray device for treating mental illness

UiO researchers test new nasal spray device for treating mental illness

Researchers at the University of Oslo have tested a new device for delivering hormone treatments for mental illness through the nose. This method was found to deliver medicine to the brain with few side effects. [More]
Psychiatric disorders may follow trigeminal neuralgia

Psychiatric disorders may follow trigeminal neuralgia

Patients with trigeminal neuralgia have an increased risk of later developing certain psychiatric disorders, a population-based study suggests. [More]
Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid is expected to save billions of dollars a year as patents for several blockbuster antipsychotic medications expire and use of generic versions of these drugs increases, according to a new study by researchers at the University of Maryland School of Medicine. These savings may provide relief from the high costs of these medications and allow policymakers to lift restrictions on patients' access, the researchers argue. [More]
Physicians may now have tools to predict people at greater risk of attempting suicide

Physicians may now have tools to predict people at greater risk of attempting suicide

People being treated for bipolar disorder and other psychiatric illnesses are at greater risk of attempting suicide, but physicians may now have tools to predict which of those individuals will attempt it and intervene early to prevent such tragedies from occurring. [More]
Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients. [More]
FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. [More]
DISC-1: schizophrenia's "Rosetta Stone" gene? An interview with Professor Kevin Fox

DISC-1: schizophrenia's "Rosetta Stone" gene? An interview with Professor Kevin Fox

The DISC-1 gene has been studied intensively over the years because people with mutations in DISC1 have a high likelihood of mental illness. DISC-1 was known to be associated with schizophrenia, bipolar disorder, major clinical depression and autism. [More]
Mice without specific brain chemical develop characteristics similar to bipolar disorder, shows study

Mice without specific brain chemical develop characteristics similar to bipolar disorder, shows study

Mice that have a particular brain chemical switched off become hyperactive and sleep for just 65 per cent of their normal time. [More]
Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition. [More]
Diagnosing psychiatric disorder may not be as important as prescribing effective treatment

Diagnosing psychiatric disorder may not be as important as prescribing effective treatment

Nailing the diagnosis of a psychiatric disorder may not be important in prescribing effective treatment, according to Mark Zimmerman, M.D., a clinical researcher at Rhode Island Hospital. His opinion editorial was published online today in the Journal of Clinical Psychiatry. [More]
Breakthrough reveals influence of schizophrenia’s 'Rosetta Stone' gene in brain development

Breakthrough reveals influence of schizophrenia’s 'Rosetta Stone' gene in brain development

Scientists have identified a critical function of what they believe to be schizophrenia's "Rosetta Stone" gene that could hold the key to decoding the function of all genes involved in the disease. [More]
New approach holds great promise for developing effective treatments for human mitochondrial diseases

New approach holds great promise for developing effective treatments for human mitochondrial diseases

Using existing drugs, such as lithium, to restore basic biological processes in human cells and animal models, researchers may have broken a long-standing logjam in devising effective treatments for human mitochondrial diseases. [More]
Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17). [More]
New study shows that lithium chloride could be used to treat arthritis

New study shows that lithium chloride could be used to treat arthritis

Lithium chloride which is used as a mood stabiliser in the treatment of mental health problems, mainly bipolar disorder, could be used to treat arthritis according to a new study. [More]
Gene function in the human brain could help reveal basis of autism

Gene function in the human brain could help reveal basis of autism

UNSW Australia scientists have discovered a link between autism and genetic changes in some segments of DNA that are responsible for switching on genes in the brain. [More]
SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

The relationship between mental and physical health is well established. But when mental and physical illnesses co-occur, patients' accounts of physical illness are sometimes arbitrarily discredited or dismissed by physicians. [More]
Georgia State University-led study identifies structural brain abnormalities in schizophrenia patients

Georgia State University-led study identifies structural brain abnormalities in schizophrenia patients

Structural brain abnormalities in patients with schizophrenia, providing insight into how the condition may develop and respond to treatment, have been identified in an internationally collaborative study led by a Georgia State University scientist. [More]
Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

The results of a randomized, double-blind, placebo-controlled clinical trial showed that Cognizin citicoline (Jarrow Formulas) was effective at reducing cocaine use, based on urine drug screens, in patients with bipolar disorder and cocaine dependence. The study, published in the American Journal of Psychiatry in Advance, included a total of 130 outpatients with bipolar I disorder and cocaine dependence, who received either Cognizin citicoline or placebo add-on therapy for 12 weeks. [More]
Use of antipsychotic drugs more common in boys than girls, research shows

Use of antipsychotic drugs more common in boys than girls, research shows

Boys are more likely than girls to receive a prescription for antipsychotic medication regardless of age, researchers have found. [More]
Advertisement